---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039051"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:47:18.237951+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enanta Q3 loss $1.86/diluted share; revenue $18.9M; positive Phase 1 RSV data

## Summary
- Net loss $39.1M ($1.86/diluted) vs. $31.7M ($1.53) in prior-year Q3; revenue $18.9M down from $19.5M.
- Cash and marketable securities $392.5M at June 30; sold 54.5% of future royalty to OMERS for $200M.
- Positive Phase 1 data for RSV L-protein inhibitor EDP-323; Phase 2 human challenge study expected early Q4 2023.
- Updated FY2023 guidance: R&D $165M-$175M; G&A $50M-$55M; royalty portion to OMERS from Q4 onward.
- Phase 2 COVID EDP-235 showed 1.0 log viral load drop in nucleocapsid-negative patients treated within 3 days.

## SEC filing metadata
- accession: 0000950170-23-039051
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017023039051/0000950170-23-039051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017023039051/enta-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039051
- JSON: https://secwatch.observer/filing/0000950170-23-039051.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039051.txt

## Key facts
- Earnings Releases
  ENANTA PHARMACEUTICALS INC reported fiscal third quarter ended June 30, 2023 results: revenue $18.9 million, net income Net loss for the three months ended June 30, 2023 was $39.1 million, or a loss of $1.86 per diluted common share, EPS $1.86 per diluted common share. Guidance reaffirmed.
  - Period: fiscal third quarter ended June 30, 2023
  - Revenue: $18.9 million
  - Net income: Net loss for the three months ended June 30, 2023 was $39.1 million, or a loss of $1.86 per diluted common share
  - EPS: $1.86 per diluted common share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 • Royalty Revenue for the Quarter was $18.9 Million WATERTOWN, Mass., Aug. 7, 2023 – Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017023039051/0000950170-23-039051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.